<?xml version='1.0' encoding='utf-8'?>
<document id="26945713"><sentence text="Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications."><entity charOffset="18-27" id="DDI-PubMed.26945713.s1.e0" text="ritonavir" /></sentence><sentence text="Nearly all HIV PIs and the integrase inhibitor elvitegravir require a pharmacokinetic enhancer in order to achieve therapeutic plasma concentrations at the desired dose and frequency" /><sentence text=" Whereas ritonavir has been the only available pharmacokinetic enhancer for more than a decade, cobicistat has recently emerged as an alternative boosting agent"><entity charOffset="9-18" id="DDI-PubMed.26945713.s3.e0" text="ritonavir" /></sentence><sentence text=" Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir"><entity charOffset="1-11" id="DDI-PubMed.26945713.s4.e0" text="Cobicistat" /><entity charOffset="16-25" id="DDI-PubMed.26945713.s4.e1" text="ritonavir" /><entity charOffset="189-199" id="DDI-PubMed.26945713.s4.e2" text="atazanavir" /><entity charOffset="204-213" id="DDI-PubMed.26945713.s4.e3" text="darunavir" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e0" e2="DDI-PubMed.26945713.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e0" e2="DDI-PubMed.26945713.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e0" e2="DDI-PubMed.26945713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e0" e2="DDI-PubMed.26945713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e1" e2="DDI-PubMed.26945713.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e1" e2="DDI-PubMed.26945713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e1" e2="DDI-PubMed.26945713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e2" e2="DDI-PubMed.26945713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26945713.s4.e2" e2="DDI-PubMed.26945713.s4.e3" /></sentence><sentence text=" Since cobicistat is a more selective CYP inhibitor than ritonavir and is devoid of enzyme-inducing properties, differences are expected in their interaction profiles with some co-medications"><entity charOffset="57-66" id="DDI-PubMed.26945713.s5.e0" text="ritonavir" /></sentence><sentence text=" Drugs whose exposure might be altered by ritonavir but unaltered by cobicistat are drugs primarily metabolized by CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 or drugs undergoing mainly glucuronidation"><entity charOffset="42-51" id="DDI-PubMed.26945713.s6.e0" text="ritonavir" /></sentence><sentence text=" Thus, co-medications should be systematically reviewed when switching the pharmacokinetic enhancer to anticipate potential dosage adjustments" /><sentence text="" /></document>